Perspective Therapeutics appoints Maya Martinez-Davis, GSK US President, to board

Perspective Therapeutics, Inc.

Board expanded to 6; Martinez-Davis appointed as independent director effective Sept 3, 2025.
She serves on Compensation and Nominations Committees; receives $60K annual cash retainer plus 75K options (max $450K fair value) vesting over 36 months.
Martinez-Davis brings 20+ years pharma experience; currently leads GSK's US commercial business since 2019.
Her prior roles include President of biopharma Latin America at Merck KGaA and senior roles at Pfizer and Mirati board.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.